Lentivector expressing HBsAG and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAG transgenic mice

Yuan Hong, Yibing Peng, Michael Mi, Haiyan Xiao, David H Munn, Gui Qiang Wang, Yukai He

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Even though hepatitis B virus(HBV) vaccines effectively prevent new cases of HBV infection, with approximately 350 million patients worldwide, chronic HBV infection remains a major health problem because of the associated complications (such as liver cirrhosis and hepatocellular carcinoma) and the limited treatment options. Immunotherapy has the potential to effectively control HBV replication. In this current study, we found that recombinant lentivectors could induce potent HBV surface antigen (HBsAg) specific T cell responses and humoral immune responses. Tagging the HBsAg with immunoglobulin Fc fragment further substantially increased the HBsAg specific immune responses. Remarkably, the HBSFc-lv lentivector could effectively break immune tolerance and induce potent HBsAg specific adaptive immune responses in HBsAg transgenic (Tg) mice with low serum level of HBsAg. More importantly, the induction of HBsAg specific immune responses in Tg mice accompanied seroconversion from HBsAg to anti-HBsAg antibody (anti-HBsAb). Our study demonstrated the potential of utilizing lentivector to treat chronic HBV infection following reduction of viral load with antiviral drug therapy.

Original languageEnglish (US)
Pages (from-to)3909-3916
Number of pages8
JournalVaccine
Volume29
Issue number22
DOIs
StatePublished - May 17 2011

Fingerprint

Immunoglobulin Fc Fragments
surface antigens
seroconversion
Surface Antigens
immunoglobulins
Transgenic Mice
Hepatitis B virus
immune response
genetically modified organisms
antigens
Antigens
mice
Virus Diseases
chronic hepatitis B
Chronic Hepatitis B
infection
Immune Tolerance
Hepatitis B Vaccines
antiviral agents
Seroconversion

Keywords

  • Chronic HBV infection
  • Genetic immunization
  • Hepatitis B virus
  • Immunotherapy
  • Lentivector
  • Vaccines

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Lentivector expressing HBsAG and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAG transgenic mice. / Hong, Yuan; Peng, Yibing; Mi, Michael; Xiao, Haiyan; Munn, David H; Wang, Gui Qiang; He, Yukai.

In: Vaccine, Vol. 29, No. 22, 17.05.2011, p. 3909-3916.

Research output: Contribution to journalArticle

@article{1df3f3db40c7458ea81faeca1ccf445d,
title = "Lentivector expressing HBsAG and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAG transgenic mice",
abstract = "Even though hepatitis B virus(HBV) vaccines effectively prevent new cases of HBV infection, with approximately 350 million patients worldwide, chronic HBV infection remains a major health problem because of the associated complications (such as liver cirrhosis and hepatocellular carcinoma) and the limited treatment options. Immunotherapy has the potential to effectively control HBV replication. In this current study, we found that recombinant lentivectors could induce potent HBV surface antigen (HBsAg) specific T cell responses and humoral immune responses. Tagging the HBsAg with immunoglobulin Fc fragment further substantially increased the HBsAg specific immune responses. Remarkably, the HBSFc-lv lentivector could effectively break immune tolerance and induce potent HBsAg specific adaptive immune responses in HBsAg transgenic (Tg) mice with low serum level of HBsAg. More importantly, the induction of HBsAg specific immune responses in Tg mice accompanied seroconversion from HBsAg to anti-HBsAg antibody (anti-HBsAb). Our study demonstrated the potential of utilizing lentivector to treat chronic HBV infection following reduction of viral load with antiviral drug therapy.",
keywords = "Chronic HBV infection, Genetic immunization, Hepatitis B virus, Immunotherapy, Lentivector, Vaccines",
author = "Yuan Hong and Yibing Peng and Michael Mi and Haiyan Xiao and Munn, {David H} and Wang, {Gui Qiang} and Yukai He",
year = "2011",
month = "5",
day = "17",
doi = "10.1016/j.vaccine.2011.03.025",
language = "English (US)",
volume = "29",
pages = "3909--3916",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "22",

}

TY - JOUR

T1 - Lentivector expressing HBsAG and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAG transgenic mice

AU - Hong, Yuan

AU - Peng, Yibing

AU - Mi, Michael

AU - Xiao, Haiyan

AU - Munn, David H

AU - Wang, Gui Qiang

AU - He, Yukai

PY - 2011/5/17

Y1 - 2011/5/17

N2 - Even though hepatitis B virus(HBV) vaccines effectively prevent new cases of HBV infection, with approximately 350 million patients worldwide, chronic HBV infection remains a major health problem because of the associated complications (such as liver cirrhosis and hepatocellular carcinoma) and the limited treatment options. Immunotherapy has the potential to effectively control HBV replication. In this current study, we found that recombinant lentivectors could induce potent HBV surface antigen (HBsAg) specific T cell responses and humoral immune responses. Tagging the HBsAg with immunoglobulin Fc fragment further substantially increased the HBsAg specific immune responses. Remarkably, the HBSFc-lv lentivector could effectively break immune tolerance and induce potent HBsAg specific adaptive immune responses in HBsAg transgenic (Tg) mice with low serum level of HBsAg. More importantly, the induction of HBsAg specific immune responses in Tg mice accompanied seroconversion from HBsAg to anti-HBsAg antibody (anti-HBsAb). Our study demonstrated the potential of utilizing lentivector to treat chronic HBV infection following reduction of viral load with antiviral drug therapy.

AB - Even though hepatitis B virus(HBV) vaccines effectively prevent new cases of HBV infection, with approximately 350 million patients worldwide, chronic HBV infection remains a major health problem because of the associated complications (such as liver cirrhosis and hepatocellular carcinoma) and the limited treatment options. Immunotherapy has the potential to effectively control HBV replication. In this current study, we found that recombinant lentivectors could induce potent HBV surface antigen (HBsAg) specific T cell responses and humoral immune responses. Tagging the HBsAg with immunoglobulin Fc fragment further substantially increased the HBsAg specific immune responses. Remarkably, the HBSFc-lv lentivector could effectively break immune tolerance and induce potent HBsAg specific adaptive immune responses in HBsAg transgenic (Tg) mice with low serum level of HBsAg. More importantly, the induction of HBsAg specific immune responses in Tg mice accompanied seroconversion from HBsAg to anti-HBsAg antibody (anti-HBsAb). Our study demonstrated the potential of utilizing lentivector to treat chronic HBV infection following reduction of viral load with antiviral drug therapy.

KW - Chronic HBV infection

KW - Genetic immunization

KW - Hepatitis B virus

KW - Immunotherapy

KW - Lentivector

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=80051769980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051769980&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.03.025

DO - 10.1016/j.vaccine.2011.03.025

M3 - Article

VL - 29

SP - 3909

EP - 3916

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 22

ER -